choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Eloxatine

Eloxatine Newsletter
  • Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER 05 Feb 2021 06:30 GMT

    … financial indicators. Pharmaceuticals Fourth-quarter 2020 Pharmaceutical sales increased … orphan drug designation from the FDA for the treatment of … investigator-initiated Phase 3 trials. FDA has designated SAR442257, ( … 158    -5.8  % Eloxatine 198    -0.5  % …

  • Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER 29 Oct 2020 06:30 GMT

    … that will deliver promising medicines to address significant patient … granted orphan drug designation by the FDA for the treatment of …   117    -7.8  % Eloxatine 146    -7.5  % - … statement Third Quarter 2020 Pharmaceuticals Consumer Healthcare Vaccines Others …

  • Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation 29 Jul 2020 05:30 GMT

    … indicators. Pharmaceuticals Second-quarter 2020 Pharmaceutical sales … Medical Products Administration (NMPA) in China approved Dupixent® (dupilumab) for the treatment … S. Food and Drug Administration (FDA) approved Dupixent® …     -12.5  % Eloxatine 94    -11.9  …

  • Sanofi at forefront of fight against COVID-19 in Q1 2020 24 Apr 2020 05:30 GMT

    … trial programs and to advance our pipeline of potentially transformative medicines … FDA), in combination with pomalidomide and dexamethasone (pom-dex) for the treatment … 38 -17.4% Eloxatine 47 -11.1% … First Quarter 2020 Pharmaceuticals Consumer Healthcare …

  • Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 06 Feb 2020 06:30 GMT

    … European Generics business. Pharmaceuticals Fourth-quarter Pharmaceutical sales were up … U.S. Food and Drug Administration (FDA) and Health Canada … separate clinical trials evaluating olipudase alfa for the treatment of … 10.5% 10.5%   Eloxatine 5 -37.5% -37. …

  • Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 02 Nov 2017 06:31 GMT

    … *CS: constant structure Pharmaceuticals Third-quarter Pharmaceuticals sales were up 3 … immunosuppressant drug cyclosporine A (CSA), or when this treatment is medically … 6.8% 2.3%   Eloxatine 8 28.6% 14.3% … Start of Phase 3 trials in combination therapies in …

  • Sanofi Q3 well on track 31 Oct 2019 06:30 GMT

    … and European Generics Pharmaceuticals Third-quarter Pharmaceutical sales were up … U.S. Food and Drug Administration (FDA) and Health Canada … kind, to develop transformative treatments for patients while significant … -4.5% -4.5%   Eloxatine 7 -12.5% -12.5% …

  • Sanofi delivered solid growth in Q2 2019 29 Jul 2019 05:30 GMT

    … and European Generics Pharmaceuticals Second-quarter Pharmaceutical sales were up … .S. Food and Drug Administration (FDA) accepted for review … ICS) plus another medicinal product for maintenance treatment. In May, … 3.6% 6.0%   Eloxatine 10 -37.5% -37. …

  • Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER 26 Apr 2019 05:31 GMT

    … -0.6% at CS Pharmaceuticals First-quarter Pharmaceutical sales were up 3 … medicinal product for maintenance treatment. In the first quarter, the U.S. FDA … results from two phase 3 trials evaluating Dupixent® in patients … 47 7 .0% 9 .3% Eloxatine 6 -14 .3% -14 …

Satisfied with the content?

Continue to create your account.